Rütter Anita, Luger Thomas A
Department of Dermatology, University of Münster, Germany.
Curr Opin Investig Drugs. 2002 May;3(5):713-9.
Intravenous immunoglobulins (IVIgs) exert a variety of immunomodulating activities and are therefore increasingly being used for the treatment of immune-mediated as well as autoimmune diseases. Although the exact mode of action is still poorly understood, the efficacy of IVIg in several diseases, such as thrombocytopenic pupura and Kawasaki disease, has been proven in clinical trials. According to some uncontrolled clinical studies and many case reports there is evidence for a high efficacy of IVIg in the treatment of skin diseases such as autoimmune blistering diseases, lupus erythematosus, dermatomyositis, scleroderma, toxic epidermal necrolysis, atopic dermatitis, chronic autoimmune urticaria and others. In contrast to other commonly used immunomodulating therapeutic strategies, the safety profile of IVIg treatment is significantly better. This update aims to give a current view on the efficacy and safety of IVIg treatment for dermatological diseases.
静脉注射免疫球蛋白（IVIg）具有多种免疫调节活性，因此越来越多地用于治疗免疫介导性疾病以及自身免疫性疾病。尽管其确切作用方式仍知之甚少，但IVIg在多种疾病（如血小板减少性紫癜和川崎病）中的疗效已在临床试验中得到证实。根据一些非对照临床研究和许多病例报告，有证据表明IVIg在治疗自身免疫性大疱性疾病、红斑狼疮、皮肌炎、硬皮病、中毒性表皮坏死松解症、特应性皮炎、慢性自身免疫性荨麻疹等皮肤病方面具有很高的疗效。与其他常用的免疫调节治疗策略相比，IVIg治疗的安全性显著更好。本综述旨在对IVIg治疗皮肤病的疗效和安全性给出当前观点。
